In an analysis of 203 liver transplant recipients with unresectable colorectal liver metastases, overall survival was 90.9% at 1 year, 69.8% at 3 years, and 48.9% at 5 years. #ACG2026

https://www.gastroenterologyadvisor.com/reports/liver-transplant-survival-colorectal-liver-metastases/

Composite biochemical response favored #saroglitazar over placebo in US and non-US patients with primary biliary cholangitis. #ACG2026

https://www.gastroenterologyadvisor.com/reports/response-to-saroglitzar-as-second-line-treatment-for-primary-biliary-cholangitis-is-similar-in-us-other-locations/

Dermatology screening was low in both #IBD subtypes, with #UlcerativeColitis patients at lower rates (8.000%) compared with #Crohn disease patients (9.326%). #ACG2026

https://www.gastroenterologyadvisor.com/reports/bridging-preventive-care-gaps-key-to-managing-ulcerative-colitis-crohn-disease/

Use of GLP-1 RAs was associated with a lower risk for colorectal cancer among adults with obesity, but prospective trials remain necessary to establish a clear chemopreventive mechanism. #ACG2026

https://www.gastroenterologyadvisor.com/reports/glp1-ras-lower-colorectal-cancer-risk-obesity/

Sleep quality, but not sleep duration, is independently associated with metabolic dysfunction-associated steatotic liver disease (#MASLD) in adults #ACG2026

Read more: https://www.gastroenterologyadvisor.com/reports/sleep-disturbance-metabolic-associated-steatotic-liver-disease/

High rate of treatment discontinuation in patients receiving GLP-1 RAs is primarily driven by gastrointestinal adverse events, suggesting that symptom management could reduce treatment discontinuation. #ACG2026

https://www.gastroenterologyadvisor.com/reports/glp1-ra-gi-side-effects-management/

From 1999 to 2020, liver cancer mortality rates increased by 104.4% among US women, according to findings presented at #ACG2026.

Read more: https://www.gastroenterologyadvisor.com/reports/liver-cancer-mortality-rates-among-us-women-rise-sharply-over-past-two-decades/

Our team is presenting groundbreaking research at #ACG2026 in Nashville 🔬 Dr. Maria Abreu shared findings from a Phase II trial of a new oral medication for ulcerative colitis — plus our faculty presented advances in AI, virtual reality, #IBD therapy and more. Read the full article:

In #IBD patients on advanced therapy, live vaccination yields no significant rise in 30-day hospitalizations, emergency department visits, or vaccine-preventable diseases, as per data presented at #ACG2026.

https://www.gastroenterologyadvisor.com/reports/live-vaccines-safety-ibd-advanced-therapy/

Alcohol-associated #hepatitis has contributed to the rapid rise in alcohol-associated liver disease diagnoses since 2020, according to research results presented at #ACG2026.

https://www.gastroenterologyadvisor.com/reports/alcohol-associated-hepatitis-liver-transplant/

A 4-week intervention with an oral #FODMAP-targeting enzyme blend yielded clinically meaningful reductions in global symptom severity across all #IBS subtypes.#ACG2026

https://www.gastroenterologyadvisor.com/reports/targeted-ibs-enzyme-supplement-improves-symptom-severity-and-patient-outcomes/

Adults with active eosinophilic esophagitis experienced improved esophageal distensibility plateau, and endoscopic outcomes, after treatment with dupilumab. #ACG2026

https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/

In women with #IBD seeking fertility treatment, embryo transfer results in substantially higher pregnancy rates compared with intrauterine insemination. #ACG2026

https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/

In 72 pediatric autoimmune liver disease patients, plasma bile acids tracked with quantitative MRCP+ measures of bile duct dilation. Routine labs did not. Cincinnati Children's poster P6273, Tue Oct 13, 10:30–4:00 CT, presented by Thuy Nguyen. #Perspectum #ACG2026

Starting soon: Join us at 7:30 PM CT for "EoE on the Grand Ole Stage — Showcasing Solutions for Real-World Scenarios" live from #ACG2026: https://event.arraylive.com/app/login/4747c6f6-354d-4a49-8678-cacac6377613/H715VIRTUAL

Starting soon at 8:00 PM CT >> "The New Songs on the Jukebox: TL1A Blockade and Its Emerging Role in IBD" LIVE from #ACG2026: https://event.arraylive.com/app/login/0b4ceab7-b853-43a3-a756-165ac2438310/H613VIRTUAL

We'll be at the Omni Nashville Hotel in Broadway Ballroom G-K (Floor 2) TOMORROW at 7 PM CT during #ACG2026! Experts will review current evidence related to IL-23 inhibition in IBD.

For more information, please visit >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR

Join us at #ACG2026 in Nashville or virtually for expert-led discussion and a case-based game that combines collaborative challenges and friendly competition this Tuesday>> https://events.vindicocme.com/15kYU86/5a2BUm3RuSb

Join us at #ACG2026 in Nashville or virtually for a team-based game that combines collaborative challenges and friendly competition for practical learning on Sunday >> https://events.vindicocme.com/15kYU86/5a2BUm3Rstp?utm_source=bluesky&utm_medium=Post&utm_campaign=H613

Encore-worthy patient care starts at #ACG2026!

Join us in Nashville or virtually via livestream to learn more: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb